Global Acne Incidence Rose 67.3% from 1990 to 2023, Driven by Demographic Shifts

The cross-sectional GBD modeling extracted prevalence, incidence, and DALY estimates using standardized case definitions across 204 countries. Acne contributed 1.17 million DALYs in 2023, exceeding basal cell carcinoma yet comparable to psoriasis and melanoma burdens, with no mortality signal. Females accounted for 56% of cases. These figures derive from modeled data rather than uniform primary surveillance, incorporating health-care utilization patterns that likely improved detection in high-income regions.

Rising age-standardized rates suggest factors beyond population growth, including possible shifts in diet, urban pollution exposure, and delayed childbearing that prolong hormonal influences on pilosebaceous units. The original MedicalXpress summary omitted how GBD under-ascertainment in low-resource settings may compress true disparities; earlier GBD 2019 acne papers already flagged similar upward trajectories in East Asia and Latin America. Socioeconomic gradients in treatment access remain unquantified here.

Future modeling must integrate intervention scenarios such as topical retinoid scale-up and dietary trials. Without them, projections risk over-attributing burden to demographics alone. Next studies require longitudinal cohorts linking incidence to modifiable exposures rather than relying on autoregressive forecasts.

Regulatory bodies should prioritize acne within skin-disease funding allocations, given DALY parity with select cancers. Improved primary-care coding and patient-reported outcome measures will tighten uncertainty intervals that currently exceed 20% in low-data regions.